The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features, leading to rapid progression and treatment resistance. The third symposium on treatment-induced NEPC, held from 21 to 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united leading global researchers and clinicians. Sponsored by the Vancouver Prostate Centre (VPC), Canadian Institute of Health Research, Prostate Cancer Foundation Canada and Pharma Planter Inc, the event focused on the latest NEPC research and innovative treatment strategies. Co-chaired by Drs. Yuzhuo Wang and Martin Gleave, the symposium featured sessions on NEPC's historical context, molecular pathways, epigenetic regulation and the role of the tumor microenvironment and metabolism in its progression. Keynotes from experts like Dr. Himisha Beltran and Dr. Martin Gleave highlighted the complexity of NEPC. The Emerging Talent session showcased new research, pointing to the future of NEPC treatment. The symposium concluded with a consensus on the need for early detection, targeted therapies and personalized medicine to effectively combat NEPC, emphasizing the importance of global collaboration in advancing NEPC understanding and treatment.
Authors
- Joshua Scurll
- Natasha Kyprianou (ORCID: https://orcid.org/0000-0002-8713-3599)
- Francesco Crea (ORCID: https://orcid.org/0000-0002-4903-2973)
- David S. Rickman (ORCID: https://orcid.org/0000-0001-7420-5883)
- Elena Jachetti (ORCID: https://orcid.org/0000-0001-6483-7350)
- Triparna Sen (ORCID: https://orcid.org/0000-0003-4673-7481)
- Himisha Beltran (ORCID: https://orcid.org/0000-0003-3259-2226)
- Mads Daugaard (ORCID: https://orcid.org/0000-0001-8383-055X)
- Michael Haffner (ORCID: https://orcid.org/0000-0001-9906-6832)
- Martin Gleave (ORCID: https://orcid.org/0000-0003-4235-0167)
- Xuesen Dong (ORCID: https://orcid.org/0000-0002-3115-3371)
- Priyadarsini Gangadharannambiar (ORCID: https://orcid.org/0009-0009-6265-031X)
- Shusuke Akamatsu (ORCID: https://orcid.org/0000-0002-1394-7506)
- Amina Zoubeidi (ORCID: https://orcid.org/0000-0002-0498-142X)
- Helen He Zhu (ORCID: https://orcid.org/0000-0003-0290-5527)
- Benyi Li (ORCID: https://orcid.org/0000-0001-6242-5117)
- Yu Wang (ORCID: https://orcid.org/0000-0003-1753-0289)
- Yuzhuo Z. Wang (ORCID: https://orcid.org/0000-0002-9749-8591)
- Yuchao Ni
- Cassandra Jingjing Cui
- Michael Cox (ORCID: https://orcid.org/0000-0001-6468-6046)
- Hansen He
- Itzel Astiazarán Rascón
- Christopher E Ong
- Ace Mingchen Shi
Institutions
- University Health Network (CA)
- University of British Columbia (CA)
- Shanghai Jiao Tong University (CN)
- University of Toronto (CA)
- The Open University (GB)
- Cornell University (US)
- Princess Margaret Cancer Centre (CA)
- Fred Hutch Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- University of Kansas Medical Center (US)
- State Key Laboratory of Oncogene and Related Genes (CN)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Weill Cornell Medicine (US)
- Nagoya University (JP)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Epigenomics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1080/17501911.2024.2391729
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Prostate Cancer Foundation
- Institute of Cancer Research